AdventHealth Translational Research Institute
adventhealth.comTotal trials
56
Active
30
Phase 3
0
Total enrollment
5,505
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| SGLT-2 inhibitor | — | — | — | — | — | 1 | |
| Glucagon | — | — | — | — | — | 3 | |
| SGLT2 inhibitor | — | — | — | — | — | 1 |
Next readouts
- 2017-01-13
- 2018-02-14
- 2024-07-23
- 2030-04
Top conditions
- Obesity12
- Type 2 Diabetes8
- Diabetes6
- Type 1 Diabetes4
- Sarcopenia3
- Metabolic Diseases3
- Aging3
- Colonic Neoplasms2
Frequently asked questions about AdventHealth Translational Research Institute
- How many clinical trials does AdventHealth Translational Research Institute have on ClinicalTrials.gov?
- AdventHealth Translational Research Institute is listed as the lead sponsor on 56 clinical trials in ClinicalTrials.gov, 30 of which are currently active (recruiting, enrolling, or ongoing).
- How many of AdventHealth Translational Research Institute's trials are in Phase 3?
- 0 of AdventHealth Translational Research Institute's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does AdventHealth Translational Research Institute focus on?
- AdventHealth Translational Research Institute's most-studied conditions on ClinicalTrials.gov are Obesity, Type 2 Diabetes, Diabetes, Type 1 Diabetes, Sarcopenia.
- When are AdventHealth Translational Research Institute's next clinical trial readouts?
- AdventHealth Translational Research Institute has 4 upcoming primary-completion readouts tracked here; the soonest is “To Determine Tolerability to Glucagon Infusion in Obese Subjects”, expected around 2017-01-13.